Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis
NCT ID: NCT02873949
Last Updated: 2019-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2016-04-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Bacterial factors: major risk factor. Although the presence of periodontopathogen bacteria is necessary for the onset of periodontitis, these microorganisms are not sufficient for progression of all periodontal disease.
* Immune factor: host immune response modulates the disease evolution to destruction or recovery. The most studied cytokine in periodontology is IL-1 that induces various immune reactions and bone resorption directly or indirectly through the stimulation of prostaglandin E2 (PGE2) release. PGE2 activates the matrix metalloproteinases that are responsible of the degradation of bone extracellular matrix.
Cytokine production, especially TNFα, IL-1β, IL-6 and IL-8, by some immune cells is modulated by new identified molecules such as Triggering Receptor Expressed on Myeloid cells (TREM) whose role in periodontitis is unknown.
The purpose of this study is to compare concentrations of soluble TREM-1 and TREM-2 markers in infected sites and in healthy sites in patients affected by periodontitis.
Other purposes are
1. Comparison of soluble TREM-1 and TREM-2 concentrations in healthy sites in patients affected by periodontitis and in healthy patients
2. Comparison of soluble TREM-1 and TREM-2 concentrations before and after etiologic periodontitis treatment
3. Estimation of the correlation between soluble TREM-1 and TREM-2 concentrations and clinical signs of periodontitis
4. Description of soluble TREM-1/TREM-2 ratio before and after etiologic treatment
5. Description of presence of some bacteria in sites analyzed for soluble TREM-1 and TREM-2
6. Search for the most observed bacteria in presence of high concentrations of soluble TREM-1 and TREM-2 before and after etiologic treatment
7. Evaluation of the impact of psychological stress measured through salivary cortisol level in saliva on TREM-1 and -2 expression
8. Evaluation of the impact of psychological stress through stress and anxiety auto-questionnaires (Spielberger and Cohen) on soluble TREM-1 and TREM-2 concentrations in crevicular fluid of healthy and pathologic teeth.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TREM-1 Pathway in Predicting Treatment Outcomes in Periodontitis
NCT06715176
Immunoregulation of Periodontal Disease
NCT00702429
IL-32 Levels in Patients With Chronic Periodontitis
NCT02632981
Effect of Periodontal Treatment on Salivary Biomarkers
NCT02159781
Transcriptome, Proteome and Microbiome Profile in Periodontal and Peri-implant Diseases
NCT06262035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Periodontitis patients
30 patients consulting at Odontology department for periodontal treatment
Crevicular samples (1-10µl)
In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment
In non-periodontitis individuals: 2 samples from 1 site
Saliva samples (1ml)
Etiologic treatment
education on oral hygiene, scaling and root planing
Psychometric tests
Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
2. Control
10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
Crevicular samples (1-10µl)
In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment
In non-periodontitis individuals: 2 samples from 1 site
Saliva samples (1ml)
Psychometric tests
Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Crevicular samples (1-10µl)
In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment
In non-periodontitis individuals: 2 samples from 1 site
Saliva samples (1ml)
Etiologic treatment
education on oral hygiene, scaling and root planing
Psychometric tests
Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Affiliation to social security plan
* Absence of refusal of patient
Group 1. Periodontal patients:
* Affected by moderate to severe chronic periodontitis
* At least 2 distinct infected sites with periodontal pocket depth ≥ 5mm
* Having not received any root planing during last 6 months before visit
Group 2. Control:
* No periodontitis
* Consulting for dental checkup and eventually scaling
Exclusion Criteria
* Pregnant women (change in bacterial flora) and breast-feeding
* Administration of systemic antibiotherapy or any treatment influencing periodontal environment (anti-inflammatory, anti-epileptic, immune-suppressor, calcium inhibitor) during 6 months before sample collection
* Patients having a pathology needing a prophylactic antibiotherapy (possibly influencing the treatment)
* Teeth with periapical inflammatory lesions of endodontic origin
* Person under guardianship
Group 1. Periodontal patients:
\- Root planing during last 6 months before visit
Group 2. Control:
\- Periodontitis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine BISSON
Role: PRINCIPAL_INVESTIGATOR
Service Odontologie - Site Heydenreich - CHRU Nancy
Sébastien GIBOT
Role: STUDY_CHAIR
Service Réanimation Médicale - Hôpital Central - CHRU Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service Odontologie - Site Heydenreich - CHRU Nancy
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A00097-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.